[Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population].

Autor: Sivertseva SA; AO MSCH «Neftyanik», Tyumen, Russia.; Ural State Medical University, Yekaterinburg, Russia.; Kirov State Medical University, Kirov, Russia., Prilenskaya AM; AO MSCH «Neftyanik», Tyumen, Russia., Popova EV; City Clinical Hospital No. 24 of Moscow, Moscow, Russia.; Pirogov Russian National Research University, Moscow, Russia., Turova EL; Sverdlovsk Regional Clinical Hospital No. 1, Yekaterinburg, Russia., Volkova LI; Ural State Medical University, Yekaterinburg, Russia.; Sverdlovsk Regional Clinical Hospital No. 1, Yekaterinburg, Russia., Smagina IV; Altai State Medical University, Barnaul, Russia., Elchaninova EY; Altai State Medical University, Barnaul, Russia., Afanas'eva AI; Altai State Medical University, Barnaul, Russia., Goncharova ZA; Rostov State Medical University, Rostov-on-Don, Russia., Markova EA; Rostov State Medical University, Rostov-on-Don, Russia., Yarosh NM; Rostov State Medical University, Rostov-on-Don, Russia., Bakhtiiarova KZ; Bashkir State Medical University, Ufa, Russia., Sherman MA; Kirov State Medical University, Kirov, Russia., Boyko AN; Pirogov Russian National Research University, Moscow, Russia.; Federal Center of Brain and Neurotechnologies, Moscow, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (9), pp. 76-82.